Publicaciones en las que colabora con José Antonio Todolí Parra (16)

2024

  1. Exposure to different occupational chemicals and clinical phenotype of a cohort of patients with systemic sclerosis

    Autoimmunity Reviews

2023

  1. External clinical validation of automated software to identify structural abnormalities and microhaemorrhages in nailfold videocapillaroscopy images

    Clinical and experimental rheumatology, Vol. 41, Núm. 8, pp. 1605-1611

  2. Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival

    Clinical and experimental rheumatology, Vol. 41, Núm. 8, pp. 1695-1703

2022

  1. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry

    Seminars in Arthritis and Rheumatism, Vol. 55

  2. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

    Autoimmunity Reviews, Vol. 21, Núm. 10

  3. The challenge of comprehensive nailfold videocapillaroscopy practice: a further contribution

    Clinical and Experimental Rheumatology, Vol. 40, Núm. 10, pp. 1926-1932

2021

  1. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  2. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)

    Rheumatology (Oxford, England), Vol. 60, Núm. 2, pp. 872-880

2020

  1. Longterm efficacy and safety of monotherapy versus combination therapy in systemic sclerosis-associated pulmonary arterial hypertension: A retrospective RESCLE registry study

    Journal of Rheumatology, Vol. 47, Núm. 1, pp. 89-98

  2. Serodiscordant patients with systemic sclerosis: When antibody does not correspond to skin involvement

    Clinical and Experimental Rheumatology, Vol. 38, pp. S106-S114

  3. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

    Autoimmunity Reviews, Vol. 19, Núm. 5

2019

  1. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry

    Clinical Rheumatology, Vol. 38, Núm. 4, pp. 1117-1124

2018

  1. Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study (Clinical Rheumatology, (2018), 37, 4, (999-1009), 10.1007/s10067-017-3936-7)

    Clinical Rheumatology

  2. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study

    Clinical Rheumatology, Vol. 37, Núm. 4, pp. 999-1009

  3. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 6, pp. 849-857

2017

  1. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802